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Recent years have seen a resurgence of yellow fever (YF) that has also affected 
travelers.1 In 2016, Angola experienced its first major yellow fever outbreak for 
decades that rapidly spread via mobility networks within the country and to 
neighbouring nations.2 At the same time, eleven unvaccinated Chinese working in 
Angola were infected with YF virus and exported the virus to China; the first 
documented exportation of yellow fever via travelers to Asia, thereby underpinning 
the need for better preparedness for YF spread into Asia.3 In 2016, YF outbreaks also 
emerged at the gates of the most populated areas of metropolitan São Paulo and Rio 
de Janeiro in Brazil. Accordingly, the last decade also had a record number of 
international travelers infected by YF virus returning to Europe and the US.4 
 
Clinicians in non-yellow fever endemic countries have to be equally equipped to 
manage complicated yellow fever as clinicians working in yellow fever endemic 
areas, considering the high percentage of symptomatic patients who develop severe 
disease. Ho’s paper in this issue of the Journal of Travel Medicine presents one of the 
biggest cohorts of severe yellow fever cases, thus offering many lessons for clinical 
management.5 
 
YF can be a treacherous disease as its initial clinical presentation may be quite benign 
and non-specific, but can then take a fulminant course within a matter of a few days. 
Clinicians need to be highly suspicious of YF for any patient with an epidemiological 
link to potential acquisition, as earlier diagnosis may result in better management of 
this life-threatening disease. Upon diagnosis, the clinician may be able to identify 
patients with risk factors for developing more severe yellow fever, such as those 
patients with older age, or presenting with high AST levels6 and high neutrophil 
counts and YF viral load.7 In the work by Kallas et al., higher levels of creatinine and 
bilirubin, as well as coagulopathy, were associated with higher mortality in the 
univariate analyses but were interestingly not independent predictors of death as 
determined by multivariate analyses.7 Ho’s paper narrows down on those with more 
severe clinical presentation as it describes the clinical outcomes for those patients 
admitted to the Intensive Care Unit (ICU). The high frequencies of acute renal failure 
(84%), bleeding (66%) and pancreatitis (58%) is quite remarkable. The reported 
mortality of 67% was exceedingly high in a cohort that reflects the severe end of the 
clinical spectrum of YF. The in-hospital fatality rate was 67%, with the median 
interval between onset of symptoms and death being 9 days. 26 (49%) died within the 
first 72 hours in ICU. Such high case fatality rates of patients requiring ICU underpin 
the need for novel therapeutic approaches to improve patient outcome. 
 
Some laboratory findings were highly prevalent at ICU admission: high levels of 
transaminases, low platelets, greater prothrombin time, decreased factor V and 
fibrinogen, elevated ammonia, amylase and lipase, lower venous bicarbonate, 
elevated lactate, creatinine, creatinine phosphokinase, and C-reactive protein.5 
 
Ho et al. noted a high incidence of severe pancreatitis in severe yellow fever which 
has not been described before to that extent.5 Recent descriptions of this condition in 
YF-deceased patients have triggered a debate whether this condition plays a role in 
the disease pathogenesis or is restricted to a late-stage complication of multi-organ 
failure.8  
 
Due to severe metabolic acidosis, most patients required renal replacement therapy 
(73%). Continuous hemodialysis was used, and high concentrations of bicarbonate in 
the dialysis solution were required by the majority of patients. New therapy strategies 
included prophylactic anticonvulsant drugs and plasma exchange. Due to the high 
frequency of gastric bleeding, therapeutic doses of intravenous proton pump inhibitors 
were administered. Additionally, seizures occurred in 24% of patients, even without 
substantial intracranial hypertension. Due to the high frequency of seizures in the 
earlier admitted cases, it was decided to commence anticonvulsant drugs in patients 
with any symptoms of hepatic encephalopathy or arterial ammonia levels >70µmol/L. 
Before this change in management was made, 14 of 50 (28%) patients developed 
seizures.5 After initiation of prophylactic anticonvulsant therapy, 5 of 29 (17%) 
patients developed seizures. Patients with diabetes mellitus had a higher case fatality 
rate (CFR)  of 80%, while patients without diabetes had a CFR of 65%, although this 
difference did not reach statistical significance due to the small sample size.  
 
In Ho`s cohort of patients with laboratory confirmed YF admitted to the intensive, 
three patients had received YF vaccination within the past 10 days. Viscerotropic 
disease was excluded as no vaccine derived virus could be isolated. These three cases 
reinforce the fact that onset of vaccine protection only occurs 10 days after 
vaccination, which is the basis for the recommendation to travel only 10 days after 
vaccination.  
 
There were also 3 cases with breakthrough yellow fever disease regardless of 
vaccination. Despite a very high vaccine efficacy, breakthrough disease is expected as 
no vaccine, including yellow fever vaccine, has a 100% efficacy. However, a dearth 
of data exists on the risk of breakthrough disease. These 3 cases could either be due to 
true breakthrough disease, errors in vaccination records (these patients did not receive 
the vaccine), or disruption of cold chain requirements in the vaccine handling, storage 
or transportation. Stringent surveillance is needed to document breakthrough disease 
after YF vaccination, as such data will also help decide whether one life-time dose is 
sufficient, or two doses are necessary.9  
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